Dyne Therapeutics (DYN) Interest & Investment Income (2019 - 2026)
Dyne Therapeutics' (DYN) quarterly Interest & Investment Income came in at $8.8 million in Q1 2026, up 3626.38% year-on-year from $235000.0 in Q1 2025, and down 70.18% on a QoQ basis from $29.4 million in Q4 2025.
Dyne Therapeutics (DYN) Interest & Investment Income (2019 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has 8 years of Interest & Investment Income data on file, last reported at $8.8 million in Q1 2026.
- On a quarterly basis, Interest & Investment Income rose 3626.38% year-over-year to $8.8 million in Q1 2026; TTM through Mar 2026 was $46.6 million, a 12396.78% increase from a year earlier, with the FY2025 full-year figure at $29.9 million, up 497550.0% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $8.8 million, down from $29.4 million in the prior quarter.
- Over the last five years, Interest & Investment Income for DYN reached as high as $29.4 million in Q4 2025 and fell as low as -$5.3 million in Q4 2023.
- Historically, Interest & Investment Income has averaged $2.5 million across 5 years, with a median of $147000.0 in 2023.
- Across the five-year window, Interest & Investment Income sank 1512.2% in 2022 and soared 6322.25% in 2025, its largest moves.
- Year by year, Interest & Investment Income stood at $412000.0 in 2022, then tumbled by 1391.02% to -$5.3 million in 2023, then soared by 91.13% to -$472000.0 in 2024, then surged by 6322.25% to $29.4 million in 2025, then tumbled by 70.18% to $8.8 million in 2026.
- Per Business Quant data, the three most recent Interest & Investment Income figures were $8.8 million in Q1 2026, $29.4 million in Q4 2025, and $8.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | Dyne Therapeutics | 4.24 Bn | 4.24 Bn | - | 8.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.76 Mn |
| Dec 31, 2025 | 29.37 Mn |
| Sep 30, 2025 | 8.48 Mn |
| Jun 30, 2025 | 11,000.00 |
| Mar 31, 2025 | 235,000.00 |
| Dec 31, 2024 | -472,000.00 |
| Sep 30, 2024 | 718,000.00 |
| Jun 30, 2024 | -108,000.00 |
| Mar 31, 2024 | -132,000.00 |
| Dec 31, 2023 | -5.32 Mn |
| Sep 30, 2023 | 43,000.00 |
| Jun 30, 2023 | 147,000.00 |
| Mar 31, 2023 | 368,000.00 |
| Dec 31, 2022 | 412,000.00 |
| Sep 30, 2022 | 173,000.00 |
| Jun 30, 2022 | -226,000.00 |
| Mar 31, 2022 | -661,000.00 |
| Dec 31, 2021 | 749,000.00 |
| Sep 30, 2021 | 7,000.00 |
| Jun 30, 2021 | 27,000.00 |